Latin America DPP-4 Inhibitors Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Market Size (2024) | USD 754.60 Million |
| Market Size (2029) | USD 931.40 Million |
| CAGR (2024 - 2029) | 4.30 % |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Latin America DPP-4 Inhibitors Market Analysis
The Latin America Dipeptide Peptidase 4 Inhibitors Market size is estimated at USD 754.60 million in 2024, and is expected to reach USD 931.40 million by 2029, growing at a CAGR of 4.30% during the forecast period (2024-2029).
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a class of medicine that lower high blood glucose levels and are used in the treatment of type 2 diabetes. DPP4 inhibitors increase insulin and GLP-1 secretion and are commonly prescribed for people suffering from type 2 diabetes. The use of DPP4 inhibitors in patients with COVID-19 with or even without type 2 diabetes offers a simple way to reduce the virus entry and replication into the airways and to hamper the sustained cytokine storm and inflammation within the lung in patients diagnosed with COVID-19 infection.
The diabetic prevalence is high in countries in the Latin American region, and Mexico is known to have a high number of diabetic patients due to the growing prevalence of Type-2 diabetes in the country. The gradually growing obesity rate, combined with the genetic predisposition for Type-2 diabetes, acted as a prominent driver for the increase in the Type-2 diabetic population over the last 40 years. Currently, nearly 10% of the population is living with diabetes. Diabetic patients in the Latin American region mainly suffer from Type-2 diabetes, accounting for nearly 90% of the total diabetic population.
Mexico has multiple health insurance providers. The Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado (State Employee's Social Security and Social Services Institute, ISSSTE) provides coverage for government employees, and the Instituto Mexicano del Seguro Social (Mexican Social Security Institute, IMSS) covers private-sector employees. The Seguro Popular (People's Insurance) was launched to protect the working-age population against steep healthcare costs.
Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.
Latin America DPP-4 Inhibitors Market Trends
Tradjenta segment holds the highest market share in the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market in the current year
The Tradjenta segment held the highest share in the Latin America dipeptide peptidase 4 (DPP-4) inhibitors market in the current year and is expected to register a CAGR of more than 7% over the forecast period.
The Food and Drug Administration has given the prescription drug Tradjenta the go-ahead to help adults with type-2 diabetes better control their blood glucose levels. It is also used as an add-on therapy to insulin. Tradjenta should not be used in patients with type-1 diabetes or for the treatment of diabetic ketoacidosis (increased ketones in the blood or urine).
According to the IDF Diabetes Atlas, the prevalence of diabetes in Mexico reached 16.9%, or one in six adults. Additionally, 11 million adults in the country have impaired glucose tolerance, which places them at high risk of developing type-2 diabetes. Diabetes-related health expenditure in Mexico has put it in the top ten countries or territories with the highest total health expenditure. Under half of the people living with diabetes in the country are undiagnosed.
Lack of health insurance deprives the poor of access to services and puts them at risk of financial hardship. To protect the people against excessive health expenditures, many countries like Mexico have implemented mechanisms such as community-based health insurance, national health insurance, and targeted public health insurance.
The rising prevalence and various initiatives by the Mexican government are expected to drive the market's growth.
Brazil is expected to dominate the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market over the forecast period
Brazil holds the highest market share in the Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market and is also expected to register a CAGR of more than 4.7% over the forecast period.
According to the IDF Diabetes Atlas, 15.7 million adults, or 10.5%, were living with diabetes in Brazil. The cost of diabetes-related health expenditures in Brazil is the third highest in the world. In addition, 18 million adults have impaired glucose tolerance, which places them at high risk of developing type-2 diabetes. Additional data on glycaemic control in Brazil show that only 25% met the therapeutic goal of glycated hemoglobin (HbA1c) less than 7% before the pandemic, as recommended by the Brazilian Diabetes Society (SBD).
Urbanization, an aging population, declining levels of physical activity, and rising rates of overweight and obesity are just a few socioeconomic, demographic, environmental, and genetic factors that are contributing to the rise in type-2 diabetes cases in Brazil. When diabetes is undetected or inadequately treated, people with diabetes are at risk of serious and life-threatening complications, such as heart attack, stroke, kidney failure, blindness, and lower-limb amputation. These result in reduced quality of life and higher healthcare costs, which lead to a greater need for access to care.
The prevalence of diabetes is growing among all ages in Brazil. Diabetes mellitus has been of wide concern with its high prevalence, resulting in increased financial burdens for clinical systems, individuals, and governments. The government has partnered with numerous private companies to utilize their supply chains to ensure low prices for drugs. Brazil has implemented a set of reforms over the past decade to improve the distribution of doctors, develop new forms of service organization, introduce new financing models, and implement a range of quality improvement initiatives and policy frameworks to overcome risk factors such as obesity and emerging pandemic threats.
Owing to the factors mentioned above, the market is likely to grow over the forecast period.
Latin America DPP-4 Inhibitors Industry Overview
The Latin America dipeptide peptidase 4 (DPP-4) inhibitors market is consolidated, with a few major manufacturers like Eli Lilly, AstraZeneca, Merck, Boehringer Ingelheim, and Novartis gaining presence in major countries while the remaining market comprises other local or region-specific manufacturers.
Latin America DPP-4 Inhibitors Market Leaders
-
AstraZeneca
-
Novartis
-
Boehringer Ingelheim
-
Merck and Co.
-
Eli Lilly and Company
*Disclaimer: Major Players sorted in no particular order
Latin America DPP-4 Inhibitors Market News
- February, 2023: M8 Pharmaceuticals and Daewoong Pharmaceuticals announced they signed an exclusive licensing agreement whereby M8 would have the rights to register and commercialize Envlo (enavogliflozin) for Brazil and Mexico. It has aproven to be efficacious as a monotherapy, metformin combined modality therapy, metformin and gemigliptin, or other DDP4 combined modality therapy.
- February 2022: Eurofarma launched Suganon (evogliptin) in Latin America, an innovative therapy for type 2 diabetes patients. Suganon (evogliptin) is a new DPP-4 enzyme inhibitor that features the benefits of offering convenient dosing as well as a low potential for interaction with other medications, ensuring greater ease and safety for prescribers and type-2 diabetes patients.
Latin America DPP-4 Inhibitors Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions and Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
- 4.2 Market Drivers
- 4.3 Market Restraints
-
4.4 Porter's Five Forces Analysis
- 4.4.1 Bargaining Power of Suppliers
- 4.4.2 Bargaining Power of Consumers
- 4.4.3 Threat of New Entrants
- 4.4.4 Threat of Substitute Products and Services
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 Drugs
- 5.1.1 Januvia (Sitagliptin)
- 5.1.2 Onglyza (Saxagliptin)
- 5.1.3 Tradjenta (Linagliptin)
- 5.1.4 Vipidia/Nesina (Alogliptin)
- 5.1.5 Galvus (Vildagliptin)
- 5.1.6 Other Drugs
-
5.2 Geography
- 5.2.1 Mexico
- 5.2.2 Brazil
- 5.2.3 Rest of Latin America
6. MARKET INDICATORS
- 6.1 Type-1 Diabetes Population
- 6.2 Type-2 Diabetes Population
7. COMPETITIVE LANDSCAPE
-
7.1 Company Profiles
- 7.1.1 Merck And Co.
- 7.1.2 AstraZeneca
- 7.1.3 Bristol Myers Squibb
- 7.1.4 Novartis
- 7.1.5 Takeda Pharmaceuticals
- 7.1.6 Eli Lilly
- 7.1.7 Boehringer Ingelheim
- *List Not Exhaustive
- 7.2 Company Share Analysis
8. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityLatin America DPP-4 Inhibitors Industry Segmentation
Dipeptidyl peptidase 4 (DPP-4) inhibitors are a pharmacological class of drugs for treating type-2 diabetes. They help to control glycemia by increasing the levels of active incretins. The Latin America Dipeptide Peptidase 4 (DPP-4) Inhibitors Market is segmented by drugs, brands and Geography. The report offers the value (in USD) and volume (in units) for the above segments.
| Drugs | Januvia (Sitagliptin) |
| Onglyza (Saxagliptin) | |
| Tradjenta (Linagliptin) | |
| Vipidia/Nesina (Alogliptin) | |
| Galvus (Vildagliptin) | |
| Other Drugs | |
| Geography | Mexico |
| Brazil | |
| Rest of Latin America |
Latin America DPP-4 Inhibitors Market Research FAQs
How big is the Latin America Dipeptide Peptidase 4 Inhibitors Market?
The Latin America Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 754.60 million in 2024 and grow at a CAGR of 4.30% to reach USD 931.40 million by 2029.
What is the current Latin America Dipeptide Peptidase 4 Inhibitors Market size?
In 2024, the Latin America Dipeptide Peptidase 4 Inhibitors Market size is expected to reach USD 754.60 million.
Who are the key players in Latin America Dipeptide Peptidase 4 Inhibitors Market?
AstraZeneca, Novartis, Boehringer Ingelheim, Merck and Co. and Eli Lilly and Company are the major companies operating in the Latin America Dipeptide Peptidase 4 Inhibitors Market.
What years does this Latin America Dipeptide Peptidase 4 Inhibitors Market cover, and what was the market size in 2023?
In 2023, the Latin America Dipeptide Peptidase 4 Inhibitors Market size was estimated at USD 722.15 million. The report covers the Latin America Dipeptide Peptidase 4 Inhibitors Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Latin America Dipeptide Peptidase 4 Inhibitors Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Latin America DPP-4 Inhibitors Industry Report
Statistics for the 2024 Latin America DPP-4 Inhibitors market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Latin America DPP-4 Inhibitors analysis includes a market forecast outlook 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
